BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hai R, Yang D, Zheng F, Wang W, Han X, Bode AM, Luo X. The emerging roles of HDACs and their therapeutic implications in cancer. Eur J Pharmacol 2022;931:175216. [PMID: 35988787 DOI: 10.1016/j.ejphar.2022.175216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Toma G, Karapetian E, Massa C, Quandt D, Seliger B. Characterization of the effect of histone deacetylation inhibitors on CD8+ T cells in the context of aging. J Transl Med 2022;20:539. [DOI: 10.1186/s12967-022-03733-9] [Reference Citation Analysis]
2 Kundu R, Banerjee S, Baidya S, Adhikari N, Jha T. A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors. SAR and QSAR in Environmental Research 2022. [DOI: 10.1080/1062936x.2022.2145353] [Reference Citation Analysis]
3 Pellegrino M, Ricci E, Ceraldi R, Nigro A, Bonofiglio D, Lanzino M, Morelli C. From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer. Cancers (Basel) 2022;14:4401. [PMID: 36139561 DOI: 10.3390/cancers14184401] [Reference Citation Analysis]